DEVELOPMENT OF CA9-TARGETED RADIOPHARMACEUTICAL AGENTS FOR KIDNEY CANCER THERANOSTICS.

$1,127,311FY2024Defense Health AgencyDOD

University Of Wisconsin System, Madison WI

Investigators

DEVELOPMENT OF CA9-TARGETED RADIOPHARMACEUTICAL AGENTS FOR KIDNEY CANCER THERANOSTICS. · GrantIndex